• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Patient Preference and Adherence >Treatment outcomes after methylphenidate in adults with attention-deficit/hyperactivity disorder treated with lisdexamfetamine dimesylate or atomoxetine
【24h】

Treatment outcomes after methylphenidate in adults with attention-deficit/hyperactivity disorder treated with lisdexamfetamine dimesylate or atomoxetine

机译：赖斯地非米明二甲磺酸酯或阿莫西汀治疗成人注意力不足/多动症患者的哌醋甲酯治疗结果

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Purpose: To compare treatment adherence, discontinuation, add-on, and daily average consumption (DACON) among adults with attention-deficit/hyperactivity disorder receiving second-line lisdexamfetamine dimesylate (LDX) or atomoxetine (ATX), following methylphenidate. Patients and methods: A retrospective cohort study using US commercial claims databases (Q2/2009–Q3/2013). Results: At month 12, the LDX cohort (N=2,718) had a higher adherence level (proportion of days covered: 0.48 versus 0.30, P 1 (adjusted odds ratio: 0.20, 95% confidence interval: 0.15–0.25, P <0.001) than the ATX cohort. Conclusion: Adults with attention-deficit/hyperactivity disorder treated with LDX following methylphenidate had a higher treatment adherence and lower discontinuation and DACON relative to those treated with ATX following methylphenidate.
机译：目的：比较哌醋甲酯后接受二线利塞地美胺二甲磺酸盐（LDX）或阿托西汀（ATX）治疗的注意缺陷/多动障碍成年人的治疗依从性，停药，添加和每日平均消费（DACON）。患者和方法：使用美国商业索赔数据库（Q2 / 2009–Q3 / 2013）的回顾性队列研究。结果：在第12个月，LDX队列（N = 2,718）具有更高的依从性水平（工作日比例：0.48对0.30，P 1（调整后的优势比：0.20，95％置信区间：0.15-0.25，P <0.001）结论：与哌醋甲酯后接受ATX治疗的患者相比，哌醋甲酯后接受LDX治疗的患有注意力缺陷/多动障碍的成年人具有更高的治疗依从性和较低的停药率和DACON。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号